CoChat

Efficacy of small‐molecule glycogen synthase kinase‐3 inhibitors in the postnatal rat model of tau hyperphosphorylation

Open access
Selenica, M‐L, Jensen, H S, Larsen, A K, Pedersen, M L, Helboe, L, Leist, M, Lotharius, J · 2007 · British Journal of Pharmacology
Cited by 131

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background and purpose: Glycogen synthase kinase‐3 (GSK‐3) affects neuropathological events associated with Alzheimeŕs disease (AD) such as hyperphosphorylation of the protein, tau. GSK‐3β expression, enzyme activity and tau phosphorylated at AD‐relevant epitopes are elevated in juvenile rodent brains. Here, we assess five GSK‐3β inhibitors and lithium in lowering phosphorylated tau (p‐tau) and GSK‐3β enzyme activity levels in 12‐day old postnatal rats. Experimental approach: Brain levels of inhibitors following treatment in vivo were optimized based on pharmacokinetic data. At optimal doses, p‐tau (Ser 396) levels in brain tissue was measured by immunoblotting and correlated with GSK‐3β enzyme activities in the same tissues. Effects of GSK inhibitors on p‐tau, GSK‐3β activities and cell death were measured in a human neuronal cell line (LUHMES). Key results: Lithium and CHIR98014 reduced tau phosphorylation (Ser 396) in the cortex and hippocampus of postnatal rats, while Alsterpaullone and SB216763 were effective only in hippocampus. AR‐A014418 and Indirubin‐3′‐monoxime were ineffective in either brain region. Inhibition of p‐tau in brain required several‐fold higher levels of GSK inhibitors than the IC 50 values obtained in recombinant or cell‐based GSK‐3β enzyme activity assays. The inhibitory effect on GSK‐3β activity ex vivo correlated with protection against cell death and decrease of p‐tau‐ in LUHMES cells, using low μ M inhibitor concentrations. Conclusions and Implications: Selective small‐molecule inhibitors of GSK‐3 reduce tau phosphorylation in vivo. These findings corroborate earlier suggestions that GSK‐3β may be an attractive target for disease‐modification in AD and related conditions where tau phosphorylation is believed to contribute to disease pathogenesis. British Journal of Pharmacology (2007) 152, 959–979; doi:10.1038/sj.bjp.0707471; published online 1 October 2007

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707471

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 131

Metadata

Authors
Selenica, M., Jensen, H. S., Larsen, A. K., Pedersen, M. L., Helboe, L., Leist, M., & Lotharius, J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-11
Volume
152
Issue
6
Pages
959-979
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1999020480
Cited by
131
References
26
FWCI
5.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.